Trial · NCT01313182
Prevention of Surgical Site Infections: Effectiveness of Nasal Povidone-Iodine and Nasal Mupirocin
NCT01313182, Phase 4, Completed, Solventum US LLC; results first posted 2014-05-19
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Prevention of Surgical Site Infections: Effectiveness of Nasal Povidone-Iodine and Nasal Mupirocin. Trials, record NCT01313182. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01313182
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Prevention of Surgical Site Infections: Effectiveness of Nasal Povidone-Iodine and Nasal Mupirocin
- NCT number
- NCT01313182
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 1,874 participants, actual
- Lead sponsor
- Solventum US LLC
- Conditions
- Surgical Site Infection
- Interventions
- mupirocin calcium ointment, 2%, 3M Skin and Nasal Antiseptic
- First posted
- 2011-03-11
- Last updated
- 2024-12-02
- Results first posted
- 2014-05-19
- Limitations and caveats
Study failed to achieve target enrollment. The small sample size precluded a multivariate analysis. Nasal culture alone was used as a screen for S. aureus colonization, which has a sensitivity of only 48% to 66%.
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Surgical Site Infections Occurring Within 12 Months of Surgical Procedure | 12 months | Measure the rate (number and percent of patients) with deep and superficial surgical site infections after primary orthopedic surgery and primary spinal fusion surgery requiring implantation of prosthetic material. |
| Secondary | Measure Hospital Length of Stay in the Mupirocin and Povidone-iodine Groups. | Post-surgery | The hospital length of stay will be measured in the Mupirocin and Povidone-iodine groups. |
| Secondary | Measure Rate of Staphylococcus Aureus Resistance to Mupirocin. | Isolates collected and frozen immediately post-surgery. | Lab cultured isolates - they will measure rate of Staphylococcus aureus resistance to mupirocin. Both arms were sampled and tested post-op. |
| Secondary | Re-admission Rates in the Mupirocin and Povidone-iodine Groups. | 12 months | Re-admission rates in the Mupirocin and Povidone-iodine Groups. |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Surgical Site Infections Occurring Within 12 Months of Surgical Procedure | 12 months | participants | NUMBER | |
| SECONDARY | Measure Hospital Length of Stay in the Mupirocin and Povidone-iodine Groups. | Post-surgery | Data was not collected for this assessment. | ||
| SECONDARY | Measure Rate of Staphylococcus Aureus Resistance to Mupirocin. | Isolates collected and frozen immediately post-surgery. | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Re-admission Rates in the Mupirocin and Povidone-iodine Groups. | 12 months | Data was not collected for this assessment. |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Surgical Site Infections Occurring Within 12 Months of Surgical Procedure | 3M Skin and Nasal Antiseptic | 0 | participants | ||
| Surgical Site Infections Occurring Within 12 Months of Surgical Procedure | Bactroban Nasal | 5 | participants | ||
| Measure Rate of Staphylococcus Aureus Resistance to Mupirocin. | 3M Skin and Nasal Antiseptic | 21 | Participants | ||
| Measure Rate of Staphylococcus Aureus Resistance to Mupirocin. | Bactroban Nasal | 24 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | 3M Skin and Nasal Antiseptic | 842 | |
| Overall Study | STARTED | Bactroban Nasal | 855 | |
| Overall Study | COMPLETED | 3M Skin and Nasal Antiseptic | 776 | |
| Overall Study | COMPLETED | Bactroban Nasal | 763 | |
| Overall Study | NOT COMPLETED | 3M Skin and Nasal Antiseptic | 66 | |
| Overall Study | NOT COMPLETED | Bactroban Nasal | 92 |
Source ClinicalTrials.gov
Adverse events12
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Headache | Vascular disorders | 3M Skin and Nasal Antiseptic | 2 | 842 | 2 |
| other | Headache | Vascular disorders | Bactroban Nasal | 15 | 855 | 15 |
| other | Rhinorrhea | General disorders | 3M Skin and Nasal Antiseptic | 1 | 842 | 1 |
| other | Rhinorrhea | General disorders | Bactroban Nasal | 47 | 855 | 47 |
| other | Nasal irritation | General disorders | 3M Skin and Nasal Antiseptic | 8 | 842 | 8 |
| other | Nasal irritation | General disorders | Bactroban Nasal | 13 | 855 | 13 |
| other | Congestion | General disorders | 3M Skin and Nasal Antiseptic | 3 | 842 | 3 |
| other | Congestion | General disorders | Bactroban Nasal | 15 | 855 | 15 |
| other | Cough | General disorders | 3M Skin and Nasal Antiseptic | 3 | 842 | 3 |
| other | Cough | General disorders | Bactroban Nasal | 6 | 855 | 6 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | 3M Skin and Nasal Antiseptic | 0 | 842 |
| Total, all-cause mortality | Bactroban Nasal | 0 | 855 |
| Total, other adverse events | 3M Skin and Nasal Antiseptic | 15 | 842 |
| Total, other adverse events | Bactroban Nasal | 76 | 855 |
| Total, serious adverse events | 3M Skin and Nasal Antiseptic | 0 | 842 |
| Total, serious adverse events | Bactroban Nasal | 0 | 855 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 24915210 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons4
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| 3M Skin and Nasal Antiseptic vs Bactroban Nasal: Surgical Site Infections Occurring Within 12 Months of Surgical Procedure | Trial comparisons |
| 3M Skin and Nasal Antiseptic vs Bactroban Nasal: Measure Rate of Staphylococcus Aureus Resistance to Mupirocin. | Trial comparisons |
| 3M Skin and Nasal Antiseptic vs Bactroban Nasal: deaths from any cause | Trial comparisons |
| 3M Skin and Nasal Antiseptic vs Bactroban Nasal: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01313182
GET https://conductscience.org/api/trials/v1/NCT01313182/registered